Treating individuals with severe and active disease remains a substantial challenge. A recent academic, multicentre, double-blind randomised clinical trial aimed to evaluate the efficacy and safety of ...

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

A precedent for monographs of this type has been set by Le Chatelier's books on “Le Carbone” and “La Silice,” and it is not a mere coincidence that the doyen of French chemistry should ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- For adults with severe, active, nonsegmental vitiligo, baricitinib combined with narrowband ultraviolet light B (UV-B) is efficacious compared with placebo ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

Colleges and high schools around Mississippi have started to cancel classes for Tuesday ahead of projected winter storms that could leave up to four inches of snow in parts of the state.

Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR). According to GlobalData, Phase II drugs for Polymyalgia Rheumatica (PMR) have ...

The father of slain businessman, Shailen Singh said the claims that his son’s murder was related to a “love relationship" with one of his alleged killers’ girlfriend, was not new. Speaking ...

14 (78%) of 18 participants in the baricitinib group reached this endpoint compared with two (13%) of 15 participants in the placebo group (relative risk 5·8, 95% CI 3·2–10·6; adjusted p<0·0001), with ...

THE completion of a second edition of Mr. Gould's “Monograph of the Trogons,” is an event which ought not to pass by without a notice in this Journal. The first edition of this work ...

Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData, Phase II drugs for Focal Segmental ...